Foamix Establishes U.S. Subsidiary and Strengthens Executive Management With Appointment of Senior U.S. Leadership Team
06/11/2014 | 04:30pm CEST
New Senior Managers and Advisors Were Previously at Warner-Chilcott Inc., Overseeing Revenue Growth from $117 Million in 2001 to More Than $2.7 Billion in 2011.
Team Brings Expertise in Sales, Marketing, Operations, Clinical Development, Regulatory Affairs, Business Development and Legal Affairs.
Excellent Track Record in Dermatology; Experience Launching and Managing Leading Brands
REHOVOT, Israel and BRIDGEWATER, N.J. , June 11, 2014 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals, a clinical-stage, specialty pharmaceutical company focused on the development, patenting and commercialization of proprietary topical foams to address unmet needs in dermatology, today announced the establishment of its U.S. Subsidiary and appointment of five industry veterans in key operational and advisory roles. Dave Domzalski has been appointed President of Foamix Pharmaceuticals Inc., the U.S. subsidiary of Foamix Ltd., Dr. Herman Ellman has been appointed Vice President of Clinical Affairs and Alvin Howard has been appointed Vice President of Regulatory Affairs. Two new external advisors, Carl Reichel and Anthony Bruno, will both serve as Strategic Advisors to management.
Foamix Pharmaceuticals Inc. is being established in the U.S. to conduct clinical development operations, including planned U.S. clinical trials of Minocycline Foam, to manage regulatory affairs and to build commercial infrastructure.
"We are very excited to hire such a strong team of accomplished executives to build our clinical, regulatory and commercial infrastructure in the U.S.," said Dr. Dov Tamarkin, Chief Executive Officer of Foamix, Inc. "Together, this is the team that helped build Warner Chilcott into a world leader in women's health, urology, gastroenterology and dermatology, growing revenues from $117 million to more than $2.7 billion over approximately ten years."
"We would like to welcome our new U.S. management team," added Meir Eini, Chairman and Chief Operating Officer at Foamix Ltd. "As we move forward with the development of proprietary products based on our topical foam technologies, including topical minocycline foam for acne, it is critical that we have the right team in place to establish a presence in the U.S., which we expect will be our single largest market. We are confident that these new managers and advisors have the right combination of skills to execute on our plan during this exciting time for Foamix."
David (Dave) Domzalski, the newly appointed President of Foamix Pharmaceuticals Inc., is a commercial operations leader in the life science industry with an established record launching and managing leading branded pharmaceuticals and developing high-performance teams. Most recently Mr. Domzalski was Vice President of Sales & Marketing, at LEO Pharma, Inc. where he led the efforts to design and build-out the U.S. commercial operations, overseeing approximately 200 employees across multiple functional areas. He successfully managed the turnaround of Leo Pharma's psoriasis franchise from a 2-year prescription decline to an annual growth of 26%. He was responsible for the strategic re-launch of Taclonex® Topical Suspension which resulted in Taclonex being reestablished as the number one brand in the category. Prior to LEO Pharma, Mr. Domzalski was the Senior Vice President and General Manager of the Women's Health & Urology division of Azur Pharma, where he had full P&L responsibility for a start-up business unit. Before his tenure at Azur, Mr. Domzalski spent 5 years from 2003 to 2008 as the Vice President of Sales & Marketing for Warner Chilcott, where he directed all commercial efforts for in-line brands focused on therapeutic areas of dermatology, women's health and urology. His achievements at Warner Chilcott included the launch of four products within a twelve month period, including Taclonex for psoriasis and Doryx® Tablets for acne. He led the structural design, development and growth of the commercial team at Warner Chilcott from 150 to 500 employees. Earlier in his career, Mr. Domzalski, held senior sales and marketing positions at Sanofi-Synthelabo, Pharmacia, Dendrite International and Parke-Davis. Mr. Domzalski earned a Bachelor of Arts in Economics and Political Science from Muhlenberg College.
Herman Ellman, MD, the newly appointed Vice President of Clinical Affairs, brings more than 40 years of both clinical and corporate experience to Foamix. Dr. Ellman spent 13 years from 2000 to 2013 as the Senior Vice President of Clinical Development for Warner Chilcott and led the clinical development of various products in dermatology, women's health, urology, and gastroenterology. Prior to that, he spent 12 years at Berlex Laboratories, most recently as the Medical Director of Female Health Care. He was previously Chief, Critical Care Medicine and Director of Medicinal Intensive Care Unit at the Metropolitan Hospital Center in New York, Associate Professor of Clinical Medicine in the Department of Medicine at New York Medical College, Chief of the Critical Care Section and Director of the Medical Intensive Care Unit at VA Medical Center in Brooklyn, New York, and Assistant Professor in the Department of Medicine at State University New York (SUNY) Downstate Medical Center in Brooklyn, NY. He received an MD (cum laude) from SUNY-Downstate Medical Center and an A.B. in Biology (cum laude) from the University of Chicago.
Alvin Howard, the newly appointed Vice President of Regulatory Affairs has more than 30 years of experience in the pharmaceutical industry with a diverse background in regulatory affairs, compliance and quality assurance. During his career he provided regulatory oversight on the approval of 10 new drug applications, provided regulatory and quality leadership to European and US sites, and conducted successful meetings with FDA and MHRA to move development programs forward. Mr. Howard spent 13 years at Warner Chilcott, most recently as the Senior Vice President of Regulatory Affairs, where he was responsible for the development of regulatory strategies to facilitate changes to currently marketed products, and the development of regulatory strategies for R&D projects. Prior to Warner Chilcott, Mr. Howard was the Vice President of Regulatory Affairs for Roberts Pharmaceuticals, where he was responsible for providing regulatory strategies and supported the successful start of Phase III clinical programs. Prior to Roberts Pharmaceuticals, Mr. Howard spent 8 years at Solvay Pharmaceuticals, in positions of increasing responsibility in regulatory affairs and quality control. He also worked for 10 years at G.D. Searle & Co. He received a Bachelor of Science degree in Chemistry from Stillman College.
Carl Reichel, who has been appointed Strategic Advisor to management, is currently a member of the Operating Council at Consonance Capital Partners, a private equity firm focused exclusively on the U.S. Healthcare industry. Mr. Reichel was previously President of Pharmaceuticals at Warner Chilcott from 2000 to 2011. During his tenure, Mr. Reichel was instrumental in the successful IPO of Warner Chilcott and oversaw the company's growth into a multi-billion dollar enterprise. Prior to Warner Chilcott, Mr. Reichel spent 19 years at Parke-Davis, most recently as President of the United Kingdom and British Isles division, where he successfully managed growth of Lipitor's market share from less than 15% to more than 35% in two years. As Vice President, he led the U.S. sales force integration between Parke-Davis and Pfizer resulting in the successful national launch of Lipitor. Mr. Reichel earned a Bachelor of Science in Marketing and Management from Rider University, and an M.B.A. from Fairleigh Dickinson University.
Anthony Bruno, newly appointed Strategic Advisor to Foamix management, spent 12 years at Warner Chilcott, most recently as the Executive Vice President of Business Development, where he was responsible for all business development activities, including licensing, acquisitions, and divestitures. Mr. Bruno was the driving force behind Warner Chilcott's acquisition of Pfizer's female health care business, LEO Pharma's U.S. dermatology portfolio, and the acquisition of Proctor and Gamble's pharmaceutical business. Prior to Warner Chilcott, Mr. Bruno spent 16 years at Warner Lambert, most recently as General Counsel for the Company's pharmaceutical business. His major accomplishments at Warner Lambert included the Lipitor co-promotion agreement with Pfizer, the announced merger with American Home Products, and the acquisition of Warner Lambert by Pfizer. Mr. Bruno began his career as an Associate at Shearman & Sterling, where he worked on various corporate acquisitions and joint ventures. Mr. Bruno earned his J.D. with Honors from the George Washington Law School, where he was also Executive Editor of the George Washington Law Review, and his B.A. in Political Science, graduating magna cum laude, from Syracuse University.
Foamix Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on the development of patented topical foams for dermatology. The Company's lead product, Minocycline Foam, is the first-ever topical minocycline that can be used for the treatment of acne, skin infections and rosacea. Minocycline is a well-known broad-spectrum oral antibiotic, which Foamix has uniquely transformed into a topically-applied, patented-form of the drug, thereby increasing efficacy, speed of action and minimizing side effects. The Company has successfully completed Phase 2 clinical trials in acne and impetigo using its patented foam delivery platform with Minocycline. Besides these clinical stage drugs, Foamix has many pipeline drugs for dermatology and other indications using its unique topical minocycline or doxycycline and its patented delivery technologies in pre-clinical and pilot study stages.
As an IP and technology leader in topical drug development, including in foam and gel systems, Foamix has licensed foam products to pharmaceutical companies, such as Bayer, Merz and Actavis, that are at various stages of development including Phase 2, Phase 3 clinical trials and pre-NDA stages.
To date, Foamix has 29 issued patents in the United States and 65 granted patents worldwide.
This press release contains forward-looking statements that involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company's management. All statements, other than statements of historical facts, included in this press release regarding the Company's plans and objectives, expectations and assumptions of management are forward-looking statements. The use of certain words, including the words "estimate," "project," "intend," "expect," "believe," "anticipate," "will," "plan," "could," "may" and similar expressions are intended to identify forward-looking statements.
The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the Company's forward-looking statements. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements including receipt of regulatory approvals and market conditions.
The forward-looking statements are made as of this date and the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Dov Tamarkin Ph.D., CEO,
Foamix Pharmaceuticals Ltd.
2 Holzman Street,
Rehovot 76704, Israel
Tel: +972 8 9316233
David Domzalski, President,
Foamix Pharmaceuticals Inc.
520 U.S. Highway 22
Bridgewater, New Jersey 08807
Tel: +1 800 775-7936
U.S. Investor Relations:
LifeSci Advisors, LLC